1 completed, 1 recruiting, 1 terminated, 1 withdrawn. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 2 | Recruiting 1, Withdrawn 1 |
Follow Refractory Hematologic Malignancy: new trials by email Literature Review of Refractory Hematologic Malignancy trials Research Report on Refractory Hematologic Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. Tazemetostat, Tafasitamab, Lenalidomide - Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy | Phase 1 / Phase 2 | Withdrawn | Epizyme, Inc. | 2021-12-22 | 2023-08-15 | |
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Acetaminophen, Dexamethasone, Diphenhydramine - Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Completed | City of Hope Medical Center | 13 | 2020-11-18 | 2026-01-28 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) Emavusertib, Ibrutinib - Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy | Phase 1 / Phase 2 | Recruiting | Curis, Inc. | 152 | 2017-12-28 | 2026-10-06 |
Hematologic Neoplasms (4) · Hodgkin Disease (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Lymphoma, Non-Hodgkin (2) · Anemia (1) · Blast Crisis (1) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Breast Neoplasms (1) · Burkitt Lymphoma (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia, Hairy Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Acute (1)
Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Neoplasms by Site (4) · Disease Attributes (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Bone Marrow Diseases (2) · Chronic Disease (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia (2) · Leukemia, Lymphoid (2) · Leukemia, Myeloid (2)
Dexamethasone (2) · 130-nm albumin-bound paclitaxel (1) · 2C4 antibody (1) · Acetaminophen (1) · Ado-Trastuzumab Emtansine (1) · Afatinib (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Bortezomib (1) · CA-4948 (1) · CTLA-4 Antigen (1) · Calcium Dobesilate (1) · Capecitabine (1) · Carboplatin (1) · Celecoxib (1)
City of Hope Medical Center (1) · Curis, Inc. (1) · Epizyme, Inc. (1) · OHSU Knight Cancer Institute (1)
United States (4) · Czechia (1) · France (1) · Israel (1) · Italy (1) · Poland (1) · Spain (1)
Ibrahim T Aldoss (1) · Lara Davis, MD (1)
P30CA033572 (1)